drugset / Trial / NCT01104298
Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
RandomizedParallel-groupOpen-labelTreatment
Summary
The proposed investigation intends to explore if the combination of trabectedin and doxorubicin in the first line of treatment of advanced sarcomas obtains better results than doxorubicin monotherapy
Timeline
- Start
- 2009-11
- Primary completion
- 2012-12
- Completion
- 2014-05
Outcome
Outcome not reported
Stopped: “Interim analysis did not show good results for main objective”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 1.1 mg/m2 | Intravenous |